FDA Collection Of 505(b)(2) User Fees Misguided – WLF Paper
Executive Summary
FDA should only assess user fees on 505(b)(2) applications that make changes to the Indications & Usage section of labeling, according to a recent backgrounder from the Washington Legal Foundation
You may also be interested in...
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
Co-Packaged HIV Drug User Fees Likely To Be Waived By AIDS Relief Plan
Most fixed-dose combination and co-packaged versions of previously approved antiretroviral HIV therapies are unlikely to require user fees under the President's $15 bil. Emergency Plan for AIDS Relief, according to a 1draft guidance released April 15